SignalKorea
LG Chem revises licensing deal with U.S. firm for obesity drug
LG Chem revised its U.S. obesity drug licensing deal, a specific corporate catalyst.
Context
What happened: LG Chem amended its exclusive license agreement with U.S. based Rhythm Pharmaceuticals for Bivamelagon, an investigational oral obesity treatment, raising the total contract value.
Key numbers: Total contract value rose from US$305 million to US$855 million.
Why it matters: Rhythm CEO David Meeker said the commitment reflects confidence in bivamelagon's potential for patients with rare MC4R pathway diseases and long-term shareholder value. LG Chem aims to speed patient access by expanding global development.
What changed
LG Chem amended its exclusive license agreement with U.S. based Rhythm Pharmaceuticals for Bivamelagon, an investigational oral obesity treatment, raising the total contract value.
Why it matters
Rhythm CEO David Meeker said the commitment reflects confidence in bivamelagon's potential for patients with rare MC4R pathway diseases and long-term shareholder value. LG Chem aims to speed patient access by expanding global development.